Victory Capital Management Inc. Lowers Stock Holdings in Dynavax Technologies Co. (NASDAQ:DVAX)

Victory Capital Management Inc. trimmed its position in shares of Dynavax Technologies Co. (NASDAQ:DVAX) by 15.7% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 169,730 shares of the biopharmaceutical company’s stock after selling 31,576 shares during the quarter. Victory Capital Management Inc. owned 0.13% of Dynavax Technologies worth $2,167,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Charles Schwab Investment Management Inc. boosted its stake in shares of Dynavax Technologies by 2.9% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,155,080 shares of the biopharmaceutical company’s stock valued at $14,750,000 after buying an additional 32,347 shares during the period. Smartleaf Asset Management LLC boosted its stake in shares of Dynavax Technologies by 463.3% in the 4th quarter. Smartleaf Asset Management LLC now owns 2,473 shares of the biopharmaceutical company’s stock valued at $32,000 after buying an additional 2,034 shares during the period. Bank of New York Mellon Corp boosted its stake in shares of Dynavax Technologies by 4.4% in the 4th quarter. Bank of New York Mellon Corp now owns 931,328 shares of the biopharmaceutical company’s stock valued at $11,893,000 after buying an additional 39,513 shares during the period. Handelsbanken Fonder AB boosted its stake in shares of Dynavax Technologies by 9.5% in the 4th quarter. Handelsbanken Fonder AB now owns 49,700 shares of the biopharmaceutical company’s stock valued at $635,000 after buying an additional 4,300 shares during the period. Finally, C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors purchased a new position in shares of Dynavax Technologies in the 4th quarter valued at about $71,000. 96.96% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

DVAX has been the subject of several recent research reports. StockNews.com upgraded Dynavax Technologies from a “hold” rating to a “buy” rating in a research note on Monday, February 24th. William Blair reiterated an “outperform” rating on shares of Dynavax Technologies in a research note on Friday, February 21st. HC Wainwright restated a “buy” rating and set a $31.00 target price on shares of Dynavax Technologies in a research note on Friday, February 21st. Finally, The Goldman Sachs Group cut Dynavax Technologies from a “neutral” rating to a “sell” rating and decreased their target price for the stock from $15.00 to $12.00 in a research note on Tuesday, February 11th.

Dynavax Technologies Price Performance

DVAX stock opened at $13.63 on Tuesday. The business has a 50 day moving average price of $13.13 and a 200 day moving average price of $12.33. The stock has a market cap of $1.69 billion, a price-to-earnings ratio of 75.72 and a beta of 1.23. Dynavax Technologies Co. has a fifty-two week low of $9.74 and a fifty-two week high of $14.63. The company has a quick ratio of 12.34, a current ratio of 13.23 and a debt-to-equity ratio of 0.33.

Dynavax Technologies (NASDAQ:DVAX) last released its quarterly earnings results on Thursday, February 20th. The biopharmaceutical company reported $0.05 EPS for the quarter, hitting the consensus estimate of $0.05. The company had revenue of $72.03 million for the quarter, compared to analyst estimates of $72.70 million. Dynavax Technologies had a return on equity of 4.22% and a net margin of 9.85%. Equities research analysts anticipate that Dynavax Technologies Co. will post 0.32 earnings per share for the current fiscal year.

Dynavax Technologies Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.